Frontiers Case report: Short-term eculizumab use in atypical HUS
Por um escritor misterioso
Descrição
Eculizumab for Atypical Hemolytic–Uremic Syndrome
PDF] Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab
Frontiers An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies - ScienceDirect
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era
Frontiers Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
Frontiers Case report: Novel FHR2 variants in atypical Hemolytic Uremic Syndrome: A case study of a translational medicine approach in renal transplantation
The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review
PDF) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses
Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach.
Frontiers Case report: Novel FHR2 variants in atypical Hemolytic Uremic Syndrome: A case study of a translational medicine approach in renal transplantation
Frontiers Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing
PDF) A systematic review on the efficacy and safety of eculizumab for atypical hemolytic uremic syndrome
